phase 1_initiation
saveMerck & Co Inc — MK-6050 (Phase I Trial Initiation)
community read0 votes
Therapy area: Dermatology. Indication: Hidradenitis Suppurativa
Data sources
globaldata
Found something off?
same company · ±60 days · 4
- earningsMerck & Co., Inc. earningsApr 30, 2026
- phase 2 completionpembrolizumab: Merck & Co Inc — pembrolizumab (Phase II Trial Completion)Apr 30, 2026
- phase 2 completiontulisokibart: Merck & Co Inc — tulisokibart (Phase II Trial Completion)Apr 30, 2026
- pdufa(doravirine + islatravir hydrate): Merck & Co Inc — (doravirine + islatravir hydrate) (PDUFA)Apr 28, 2026
comments(0)
5-min edit window · permanent after that